Delphinus Medical Technologies

Delphinus Medical Technologies, Inc.Founded in 2010 and headquartered in Novi, US, Delphinus Medical Technologies, Inc. specializes in breast cancer screening technology.00 mn from Trinity Capital Investment.Delphinus Medical Technologies specializes in innovative breast cancer screening solutions, with its flagship product being the SoftVue™ 3D Whole Breast Ultrasound Tomography system. This FDA PMA-approved technology is specifically designed for the screening of women with dense breast tissue, addressing the significant limitations of traditional mammography, which can miss over 50% of cancers in this demographic. The SoftVue system utilizes a unique circular triple-acoustic transducer setup, incorporating over 2,000 transducer elements to deliver comprehensive imaging capabilities. By combining reflected echoes with sound speed and attenuation signals, SoftVue enables healthcare professionals to distinguish between normal and abnormal breast tissue more effectively.Delphinus Medical Technologies generates revenue through direct sales and potential partnerships with healthcare institutions, primarily focusing on B2B transactions. The business model revolves around the sale and installation of the SoftVue system, which is complemented by ongoing service agreements and training for medical staff. Customers, including hospitals and imaging centers, benefit from enhanced screening capabilities that improve cancer detection rates, particularly in women with dense breast tissue. Revenue is derived from the initial purchase of the SoftVue system, as well as follow-up services such as maintenance and software updates.In June 2023, Delphinus Medical Technologies, Inc.

1. Series D

   Aug 30, 2022

   Amount

   $30M

   Investors

   Locked

2. Series C

   Sep 10, 2015

   Amount

   $40M

   Investors

   Locked

3. Series B

   Sep 3, 2013

   Amount

   $11M

   Investors

   Locked

4. Series A

   May 25, 2010

   Amount

   $8M

   Investors

   Locked